Overview

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

Status:
Completed

Trial end date:
2020-12-10

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well apalutamide, abiraterone acetate, prednisone, degarelix, and indomethacin work in treating patients with prostate cancer that has spread from where it started to nearby tissue or lymph nodes before surgery. Androgen can cause the growth of tumor cells. Hormone therapy using apalutamide, abiraterone acetate, prednisone, degarelix, and indomethacin may fight prostate cancer by lowering the amount of androgen the body makes and/or blocking the use of androgen by the tumor cells.

Phase:

Phase 2

Details

Lead Sponsor:

University of Washington

Collaborators:

Janssen Scientific Affairs, LLC
National Cancer Institute (NCI)

Treatments:

Abiraterone Acetate
Androgen Receptor Antagonists
Androgens
Cortisone
Cortisone acetate
Indomethacin
Prednisone